Loxoribine (BioDeep_00000794537)
代谢物信息卡片
化学式: C13H17N5O6 (339.1178782)
中文名称: 洛索立宾
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C=CCN1C2=C(N=C(NC2=O)N)N(C1=O)C3C(C(C(O3)CO)O)O
InChI: InChI=1S/C13H17N5O6/c1-2-3-17-6-9(15-12(14)16-10(6)22)18(13(17)23)11-8(21)7(20)5(4-19)24-11/h2,5,7-8,11,19-21H,1,3-4H2,(H3,14,15,16,22)/t5-,7-,8-,11-/m1/s1
描述信息
C308 - Immunotherapeutic Agent > C210 - Immunoadjuvant > C2554 - Vaccine Adjuvant
C2140 - Adjuvant
Loxoribine (7-Allyl-8-oxoguanosine) is a guanosine analog with anti-viral and anti-tumor activities. Loxoribine is an orally bioavailable and selective Toll-like receptor (TLR) 7 agonist[1][2][3].
同义名列表
3 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- KEGGdrug: D04787
- PubChem: 135410906
- ChEMBL: CHEMBL292008
- CAS: 121288-39-9
- medchemexpress: HY-108472
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Weili Yu, Lijuan Shen, Jinming Qi, Tao Hu. Conjugation with loxoribine and mannan improves the immunogenicity of Mycobacterium tuberculosis CFP10-TB10.4 fusion protein.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
2022 Mar; 172(?):193-202. doi:
10.1016/j.ejpb.2022.02.011. [PMID: 35183715] - Ning Xu, Hang-Ping Yao, Guo-Cai Lv, Zhi Chen. Downregulation of TLR7/9 leads to deficient production of IFN-α from plasmacytoid dendritic cells in chronic hepatitis B.
Inflammation research : official journal of the European Histamine Research Society ... [et al.].
2012 Sep; 61(9):997-1004. doi:
10.1007/s00011-012-0493-z. [PMID: 22684144] - Anu S Maharjan, Darrell Pilling, Richard H Gomer. Toll-like receptor 2 agonists inhibit human fibrocyte differentiation.
Fibrogenesis & tissue repair.
2010 Nov; 3(?):23. doi:
10.1186/1755-1536-3-23. [PMID: 21106092] - Joyce E Yu, Adina K Knight, Lin Radigan, Thomas U Marron, Li Zhang, Silvia Sanchez-Ramón, Charlotte Cunningham-Rundles. Toll-like receptor 7 and 9 defects in common variable immunodeficiency.
The Journal of allergy and clinical immunology.
2009 Aug; 124(2):349-56, 356.e1. doi:
10.1016/j.jaci.2009.05.019. [PMID: 19592080] - Clett Erridge, Simon Kennedy, Corinne M Spickett, David J Webb. Oxidized phospholipid inhibition of toll-like receptor (TLR) signaling is restricted to TLR2 and TLR4: roles for CD14, LPS-binding protein, and MD2 as targets for specificity of inhibition.
The Journal of biological chemistry.
2008 Sep; 283(36):24748-59. doi:
10.1074/jbc.m800352200. [PMID: 18559343] - Stephen Fasciano, Liwu Li. Intervention of Toll-like receptor-mediated human innate immunity and inflammation by synthetic compounds and naturally occurring products.
Current medicinal chemistry.
2006; 13(12):1389-95. doi:
10.2174/092986706776872916. [PMID: 16719784] - S Gupta, B Vayuvegula, S Gollapudi. Substituted guanine ribonucleosides as B cell activators.
Clinical immunology and immunopathology.
1991 Nov; 61(2 Pt 2):S21-7. doi:
10.1016/s0090-1229(05)80034-0. [PMID: 1934610]